Daré Bioscience (DARE) Competitors $3.21 +0.03 (+0.94%) (As of 01:20 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends DARE vs. VTGN, AVTX, RANI, ANRO, SCLX, VXRT, DERM, INMB, CLLS, and IPSCShould you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Vistagen Therapeutics (VTGN), Avalo Therapeutics (AVTX), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), Scilex (SCLX), Vaxart (VXRT), Journey Medical (DERM), INmune Bio (INMB), Cellectis (CLLS), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. Daré Bioscience vs. Vistagen Therapeutics Avalo Therapeutics Rani Therapeutics Alto Neuroscience Scilex Vaxart Journey Medical INmune Bio Cellectis Century Therapeutics Daré Bioscience (NASDAQ:DARE) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Do institutionals and insiders believe in DARE or VTGN? 6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings and valuation, DARE or VTGN? Vistagen Therapeutics has lower revenue, but higher earnings than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaré Bioscience$2.81M9.85-$30.16M-$0.59-5.38Vistagen Therapeutics$1.06M68.55-$29.36M-$1.24-2.10 Do analysts recommend DARE or VTGN? Daré Bioscience currently has a consensus target price of $24.00, indicating a potential upside of 654.72%. Vistagen Therapeutics has a consensus target price of $15.00, indicating a potential upside of 474.71%. Given Daré Bioscience's higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Vistagen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daré Bioscience 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is DARE or VTGN more profitable? Daré Bioscience has a net margin of -191.65% compared to Vistagen Therapeutics' net margin of -4,521.71%. Daré Bioscience's return on equity of 0.00% beat Vistagen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Daré Bioscience-191.65% N/A -18.98% Vistagen Therapeutics -4,521.71%-36.35%-33.62% Which has more volatility & risk, DARE or VTGN? Daré Bioscience has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Does the MarketBeat Community favor DARE or VTGN? Daré Bioscience received 74 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. Likewise, 73.25% of users gave Daré Bioscience an outperform vote while only 72.31% of users gave Vistagen Therapeutics an outperform vote. CompanyUnderperformOutperformDaré BioscienceOutperform Votes35673.25% Underperform Votes13026.75% Vistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Does the media favor DARE or VTGN? In the previous week, Daré Bioscience had 12 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 13 mentions for Daré Bioscience and 1 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.75 beat Daré Bioscience's score of 0.34 indicating that Vistagen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daré Bioscience 0 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vistagen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryDaré Bioscience beats Vistagen Therapeutics on 12 of the 19 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Daré Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDaré BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.67M$6.45B$5.04B$8.81BDividend YieldN/A8.11%5.16%4.07%P/E Ratio-5.3810.78130.5317.82Price / Sales9.85243.701,183.8674.55Price / CashN/A22.1633.6132.53Price / Book-5.215.474.684.68Net Income-$30.16M$153.61M$119.23M$226.08M7 Day Performance-10.80%-2.00%-1.83%-1.04%1 Month Performance-12.64%-7.46%-3.61%1.04%1 Year Performance-21.78%31.82%31.74%26.28% Daré Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDaré Bioscience2.2167 of 5 stars$3.21+0.9%$24.00+647.7%-23.9%$27.93M$2.81M-5.4330VTGNVistagen Therapeutics3.7849 of 5 stars$2.59-0.8%$15.00+479.2%-25.4%$72.11M$1.06M0.0040Positive NewsAVTXAvalo Therapeutics2.3577 of 5 stars$10.53-3.4%N/A-47.4%$109.41M$1.92M0.0040Positive NewsRANIRani Therapeutics3.1632 of 5 stars$2.02-1.5%$11.71+479.9%+2.5%$107.89M$2.72M0.00110Analyst ForecastANROAlto Neuroscience3.8056 of 5 stars$3.99-6.6%$20.00+401.3%N/A$107.61M$210,000.000.00N/AAnalyst RevisionSCLXScilex3.4335 of 5 stars$0.56-0.8%$11.33+1,924.2%-48.7%$107.38M$46.74M0.0080Gap UpVXRTVaxart2.1538 of 5 stars$0.61-0.5%$3.00+395.9%-22.1%$107.35M$7.38M-1.48109Analyst RevisionNews CoveragePositive NewsDERMJourney Medical3.2288 of 5 stars$5.14-1.7%$9.38+82.4%N/A$106.55M$79.18M-5.5690Analyst RevisionNews CoverageINMBINmune Bio2.136 of 5 stars$4.75+4.2%$20.00+321.1%-39.1%$105.31M$160,000.00-2.0910CLLSCellectis2.4726 of 5 stars$1.88-1.6%$7.00+272.3%-38.4%$104.49M$9.19M0.00290Analyst ForecastIPSCCentury Therapeutics1.5802 of 5 stars$1.22-3.2%$11.60+850.8%-11.9%$103.74M$2.23M0.00170 Related Companies and Tools Related Companies Vistagen Therapeutics Alternatives Avalo Therapeutics Alternatives Rani Therapeutics Alternatives Alto Neuroscience Alternatives Scilex Alternatives Vaxart Alternatives Journey Medical Alternatives INmune Bio Alternatives Cellectis Alternatives Century Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DARE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daré Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
